Replies to post #203234 on Biotech Values

[DewDiligence]

Re: Opdivo vs Keytruda

I think the details of the respective studies stand to be market moving potentially. I think most of us just assume all the PD-(L)1 drugs are the same, but the fact is there are probably differences.

I agree to a certain extent. There will be some differences in clinical results; however, from a payer perspective, the two drugs are sufficiently similar that payers (and foreign governments) will hold a lot of leverage to lower contract prices of both drugs. This is a somewhat unusual case where payers can benefit by saying yes to use of an expensive drug in a setting where it is technically off-label.